ASH Clinical News November 2015

The clonoSEQ ® Process: Reveal deeper MRD Ultra-sensitive sequencing-based minimal residual disease (MRD) assessment for lymphoid cancers Universal, standardized assay Specimen flexibility Secure online results portal Learn more at clonoSEQ.com Visit us at the 57th ASH Annual Meeting Booth #247 adaptivebiotech.com